Nanyang Biologics Partners with NVIDIA, HPE, and Equinix to Launch VECURA – World’s Largest AI-Driven Natural Drug Discovery Platform
The signing event marked the beginning of the collaboration with world renowned heavyweight companies NVIDIA, HPE, and Equinix, to co-develop Vecura.
Singapore/Chennai, September 10: Nanyang Biologics (NYB), an associate company of Fischer Medical Ventures Ltd (FMV), has announced a strategic collaboration with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to launch VECURA, an AI-powered drug discovery platform designed to transform the global healthcare landscape.
VECURA combines advanced predictive AI models with a proprietary library of millions of natural compounds, creating what is expected to become the world’s largest AI-curated compound library anchored in Singapore. The platform promises to slash drug discovery timelines from the traditional 10–12 years to just a few hours.
Accelerating Discovery, Unlocking Nature
By harnessing artificial intelligence, machine learning, and virtual screening, VECURA will explore therapeutic potential within tropical flora, supported by advanced metagenomics and metaproteomics analysis. This approach enables rapid identification of promising candidates for pharmaceuticals, dietary supplements, functional foods, and personal care products—reducing costs while opening new frontiers in personalised and nature-based medicine.
NYB also plans to build a pipeline of evidence-based nutraceuticals, including CareViva™ NS, a longevity-focused formulation developed with over 26 scientists from Nanyang Technological University. FMV will serve as the global distribution partner, leveraging its network to bring these advanced wellness solutions to market.
Strategic Support and Global Reach
Ravindran Govindan, Executive Chairman & MD of FMV, said: “With the strong support of world-class companies like NVIDIA, HPE and Equinix, NYB’s supercharged VECURA platform will unleash the therapeutic potential of nature with AI. We are especially excited to extend this platform to India, the land of Ayurveda, and globalize traditional herbal medicine through AI-driven innovation.”
NYB’s collaboration not only strengthens Singapore’s position as a hub for biotechnology innovation but also supports FMV’s expansion into preventative healthcare. As India’s first indigenous MRI manufacturer, FMV sees this venture as a strategic step in building a new paradigm of affordability, accessibility, and innovation in healthcare.
Industry Impact
The initiative positions NYB and FMV at the forefront of AI-driven biotechnology, offering biotech companies worldwide a powerful platform to accelerate drug and nutraceutical development. With NVIDIA’s AI expertise, HPE’s computing capabilities, and Equinix’s global infrastructure, VECURA is set to redefine timelines and costs in drug discovery, paving the way for breakthroughs in resilience, metabolic health, and longevity.
